We’re delighted to have been shortlisted as one of the UK’s fastest-growing private companies in the inaugural Sunday Times 100 ranking. This is the first time these rankings have included private businesses.
Driven by our mission to deliver remarkable experiences at every stage of the patient journey, we’ve developed our digital products and services to ensure clinical excellence in decentralised and hybrid clinical trials, evolving to meet the changing needs of the clinical research industry at an unprecedented rate.
The result has been a 300% growth in the past four years, with a global team of experts in clinical research and a growing suite of digital products, designed to streamline payments and reimbursements and connect patients, sponsors, sites and healthcare practitioners like never before.
Our CEO, Tarquin Scadding-Hunt says, “I’m proud that, in a world where environmental, social, and governmental (ESG) concerns are more urgent than ever, mdgroup’s quantum of growth – investing in people, innovative digital health, and real impact in the field of healthcare and clinical research – has made us a sector leader to watch.
“The pandemic has pushed a patient-centred approach to the top of Big Pharma’s agenda, and it has never been more important to listen to patient voices at every stage of the clinical journey. From issues with patient care to home healthcare provider visits, mdgroup’s pioneering technology directly improves patient experience and trial outcomes for people from all backgrounds.”
mdgroup was also named as one of the UK’s fastest-scaling businesses in 2021’s Organic Growth 25 (OG25) index in recognition of our major growth and success, without significant external investment, after we grew sales from £12.8 million in 2017 to £25.7 million in 2020 and increased headcount from 42 to 89 over the same period.
